Movement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price

Market Focus07-31

On July 31, Revolution Medicines, Inc. rose 5.02% in regular trading, trading at $190.0/share, with turnover of $230 million.

On the news front, the FDA formally accepted the company's New Drug Application (NDA) for Daraxonrasib, targeting previously treated metastatic pancreatic cancer patients. This acceptance marks a critical regulatory milestone, indicating the application is complete and has entered substantive review. Concurrently, Wedbush raised its price target from $181 to $192.10, maintaining an Outperform rating, with the analyst consensus mean target at $203.85.

The regulatory progress follows Phase 3 trial data showing Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy. The European Medicines Agency has also initiated a phased accelerated review, further strengthening the global commercialization outlook. The company previously secured FDA expanded access authorization and launched the Rasolute 305 trial evaluating Zoldonrasib as a first-line pancreatic cancer therapy, broadening its oncology pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196225378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 03:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196225378","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price","media":"Market Focus","content":"<p><p>On July 31, Revolution Medicines, Inc. rose 5.02% in regular trading, trading at $190.0/share, with turnover of $230 million.</p><p>On the news front, the FDA formally accepted the company's New Drug Application (NDA) for Daraxonrasib, targeting previously treated metastatic pancreatic cancer patients. This acceptance marks a critical regulatory milestone, indicating the application is complete and has entered substantive review. Concurrently, Wedbush raised its price target from $181 to $192.10, maintaining an Outperform rating, with the analyst consensus mean target at $203.85.</p><p>The regulatory progress follows Phase 3 trial data showing Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy. The European Medicines Agency has also initiated a phased accelerated review, further strengthening the global commercialization outlook. The company previously secured FDA expanded access authorization and launched the Rasolute 305 trial evaluating Zoldonrasib as a first-line pancreatic cancer therapy, broadening its oncology pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 03:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Revolution Medicines, Inc. rose 5.02% in regular trading, trading at $190.0/share, with turnover of $230 million.</p><p>On the news front, the FDA formally accepted the company's New Drug Application (NDA) for Daraxonrasib, targeting previously treated metastatic pancreatic cancer patients. This acceptance marks a critical regulatory milestone, indicating the application is complete and has entered substantive review. Concurrently, Wedbush raised its price target from $181 to $192.10, maintaining an Outperform rating, with the analyst consensus mean target at $203.85.</p><p>The regulatory progress follows Phase 3 trial data showing Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy. The European Medicines Agency has also initiated a phased accelerated review, further strengthening the global commercialization outlook. The company previously secured FDA expanded access authorization and launched the Rasolute 305 trial evaluating Zoldonrasib as a first-line pancreatic cancer therapy, broadening its oncology pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1196225378","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196225378","pubTimestamp":1785438803,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Revolution Medicines, Inc. rose 5.02% in regular trading, trading at $190.0/share, with turnover of $230 million.On the news front, the FDA formally accepted the company's New Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"运动警报|Revolution Medicines, Inc. 常规交易上涨 5.02%，FDA 接受胰腺癌药物 NDA，Wedbush 提高目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On July 31, Revolution Medicines, Inc. rose 5.02% in regular trading, trading at $190.0/share, with turnover of $230 million.On the news front, the FDA formally accepted the company's New Drug Application (NDA) for Daraxonrasib, targeting previously treated metastatic pancreatic cancer patients. This acceptance marks a critical regulatory milestone, indicating the application is complete and has entered substantive review. Concurrently, Wedbush raised its price target from $181 to $192.10, maintaining an Outperform rating, with the analyst consensus mean target at $203.85.The regulatory progress follows Phase 3 trial data showing Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy. The European Medicines Agency has also initiated a phased accelerated review, further strengthening the global commercialization outlook. The company previously secured FDA expanded access authorization and launched the Rasolute 305 trial evaluating Zoldonrasib as a first-line pancreatic cancer therapy, broadening its oncology pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196225378","isCrawlerRequest":true}